ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,559,761 | +3.1% | 16,657 | -1.7% | 2.01% | +10.5% |
| Q2 2023 | $1,512,520 | +32.4% | 16,947 | +59.1% | 1.82% | +15.1% |
| Q1 2023 | $1,142,107 | -58.2% | 10,652 | -52.3% | 1.58% | -39.6% |
| Q4 2022 | $2,729,239 | -9.3% | 22,347 | -23.3% | 2.62% | -9.5% |
| Q3 2022 | $3,010,000 | +42.9% | 29,146 | +28.6% | 2.90% | +26.3% |
| Q2 2022 | $2,106,000 | -52.1% | 22,659 | -39.6% | 2.29% | -25.0% |
| Q1 2022 | $4,401,000 | -23.4% | 37,501 | -12.2% | 3.06% | +10.9% |
| Q4 2021 | $5,746,000 | +55.1% | 42,712 | +83.8% | 2.76% | +67.8% |
| Q3 2021 | $3,705,000 | +62.1% | 23,242 | +33.8% | 1.64% | +56.0% |
| Q2 2021 | $2,285,000 | +5.7% | 17,370 | +3.6% | 1.05% | -17.5% |
| Q1 2021 | $2,161,000 | +6.1% | 16,764 | +37.3% | 1.28% | -17.7% |
| Q4 2020 | $2,037,000 | – | 12,212 | – | 1.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 10,719,555 | $1,003,779,130 | 19.76% |
| Q Global Advisors, LLC | 285,000 | $26,687 | 17.16% |
| Finepoint Capital LP | 163,772 | $15,335,610 | 7.64% |
| Avoro Capital Advisors LLC | 3,670,000 | $343,658,800 | 5.36% |
| Spyglass Capital Management LLC | 614,618 | $57,552,830 | 4.51% |
| Sofinnova Investments, Inc. | 754,032 | $70,607,556 | 4.45% |
| Saturn V Capital Management LP | 112,473 | $10,531,972 | 4.41% |
| DAFNA Capital Management LLC | 136,212 | $12,754,892 | 3.97% |
| ARS Investment Partners, LLC | 285,918 | $26,773,362 | 3.32% |
| Ghost Tree Capital, LLC | 85,000 | $7,959,400 | 2.62% |